INT65545

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.79
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 35
Total Number 36
Disease Relevance 20.80
Pain Relevance 1.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
Anatomy Link Frequency
pancreas 2
A431 1
hepatocyte 1
epidermis 1
nucleus 1
EGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 85 98.72 Very High Very High Very High
antagonist 119 98.64 Very High Very High Very High
Chronic pancreatitis 4 96.96 Very High Very High Very High
Inflammation 47 87.68 High High
cytokine 14 84.36 Quite High
Pain 44 63.88 Quite High
abdominal pain 13 60.96 Quite High
Bile 19 50.80 Quite High
imagery 43 50.00 Quite Low
Cannabinoid 36 50.00 Quite Low
Disease Link Frequency Relevance Heat
Apoptosis 342 100.00 Very High Very High Very High
Cholangiocarcinoma 157 99.84 Very High Very High Very High
Pancreatic Cancer 85 99.84 Very High Very High Very High
Prostate Cancer 50 99.72 Very High Very High Very High
Cancer 924 99.66 Very High Very High Very High
Carcinoma 35 99.62 Very High Very High Very High
Fever 57 99.22 Very High Very High Very High
INFLAMMATION 55 98.60 Very High Very High Very High
Sprains And Strains 5 98.18 Very High Very High Very High
Targeted Disruption 15 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is produced by immunizing a XenoMouse strain of mice with human cervical epidermal carcinoma cell line A431, a cell line known for its abundance of EGFR on the cell surface.21,22 Unlike chimeric antibodies, fully humanized monoclonal antibodies do not contain any amount of foreign elements (ie, mouse protein) and thus do not generate human antimouse antibodies.
Localization (abundance) of EGFR in A431 associated with carcinoma and sprains and strains
1) Confidence 0.79 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.94 Pain Relevance 0
This is the first demonstration of subcellular localization of TGF-alpha and EGFR in the normal and diseased human and hamster pancreas.
Localization (localization) of EGFR in pancreas
2) Confidence 0.78 Published 1995 Journal Teratog., Carcinog. Mutagen. Section Abstract Doc Link 8867879 Disease Relevance 0.52 Pain Relevance 0.12
Cellular and subcellular localization of transforming growth factor-alpha and epidermal growth factor receptor in normal and diseased human and hamster pancreas.
Localization (localization) of epidermal growth factor receptor in pancreas
3) Confidence 0.78 Published 1995 Journal Teratog., Carcinog. Mutagen. Section Title Doc Link 8867879 Disease Relevance 0.65 Pain Relevance 0.18
In gastrointestinal carcinomas, monoclonal antibodies targeting EGFR/EGFR-1 (cetuximab, panitumomab) and EGFR-2 (trastuzumab) have become part of the standard treatment armamentaria against colorectal and gastric cancers, respectively [4,5].
Localization (targeting) of EGFR-2 associated with carcinoma and stomach cancer
4) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2972285 Disease Relevance 0.72 Pain Relevance 0.03
In gastrointestinal carcinomas, monoclonal antibodies targeting EGFR/EGFR-1 (cetuximab, panitumomab) and EGFR-2 (trastuzumab) have become part of the standard treatment armamentaria against colorectal and gastric cancers, respectively [4,5].
Localization (targeting) of EGFR associated with carcinoma and stomach cancer
5) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2972285 Disease Relevance 0.71 Pain Relevance 0.03
In gastrointestinal carcinomas, monoclonal antibodies targeting EGFR/EGFR-1 (cetuximab, panitumomab) and EGFR-2 (trastuzumab) have become part of the standard treatment armamentaria against colorectal and gastric cancers, respectively [4,5].
Localization (targeting) of EGFR associated with carcinoma and stomach cancer
6) Confidence 0.75 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2972285 Disease Relevance 0.72 Pain Relevance 0.03
A variant of EGFR extracellular region
Localization (region) of EGFR
7) Confidence 0.75 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.53 Pain Relevance 0
EGFR targeting TKIs and mAbs has been associated with several side effects, especially within organs with high levels of proliferation and EGFR expression, most notably the epidermis and intestinal lining.
Localization (targeting) of EGFR in epidermis
8) Confidence 0.75 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2990321 Disease Relevance 0.86 Pain Relevance 0
Although both EGFR and HER-2 (+ve) are
Localization (+ve) of EGFR
9) Confidence 0.75 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.50 Pain Relevance 0
which is capable of targeting both the EGFR and HER-2/neu tyrosine kinases that
Localization (targeting) of EGFR
10) Confidence 0.75 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.40 Pain Relevance 0
It is not known if newer automated, quantitative immunohistochemical techniques, which allow for more precise quantification of EGFR levels as well as subcellular localization will have more power to predict for cetuximab response.
Localization (localization) of EGFR
11) Confidence 0.74 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2921255 Disease Relevance 0.30 Pain Relevance 0
The same downregulation of total EGFR elicited by sulindac sulfide and sulfone was found using this antibody (data not shown), confirming that these results are not peculiar to a single EGFR epitope or a result of an artifact of the use of a single antibody.
Localization (epitope) of EGFR
12) Confidence 0.74 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.25 Pain Relevance 0
The same downregulation of total EGFR elicited by sulindac sulfide and sulfone was found using this antibody (data not shown), confirming that these results are not peculiar to a single EGFR epitope or a result of an artifact of the use of a single antibody.
Localization (epitope) of EGFR
13) Confidence 0.74 Published 2005 Journal J Carcinog Section Body Doc Link PMC1208922 Disease Relevance 0.25 Pain Relevance 0
Cancer cells expressing EGFR and ErbB2 are nonresponsive to inhibitors targeting one of these two proteins.63 Similarly, overexpression of ErbB3 also confers resistance to EGFR inhibitors.64 Expression of hepatocyte growth factor and c-Met dependent signaling is also an alternative pathway for signaling conferring resistance (seen in approximately 20% of patients with acquired resistance to TKIs).65 Finally, interactions between EGFR and the insulin growth factor receptor (IGF-1R) can provide resistance to agents targeting EGFR.66
Localization (targeting) of EGFR in hepatocyte associated with cancer
14) Confidence 0.74 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886327 Disease Relevance 0.38 Pain Relevance 0
Similarly, panitumumab is a fully humanized monoclonal IgG2 antibody, directed against EGFR.
Localization (directed) of EGFR
15) Confidence 0.73 Published 2009 Journal OncoTargets and therapy Section Abstract Doc Link PMC2886332 Disease Relevance 0.59 Pain Relevance 0
Panitumumab (ABX-EGF, E.7.6.3, Vectibix®), is a highaffinity, fully humanized monoclonal IgG2 antibody, directed against EGFR, generated in XenoMouse® (Abjenix, Fremont, CA; transgenic mouse capable of producing human antibodies).
Localization (directed) of EGFR associated with targeted disruption
16) Confidence 0.73 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.99 Pain Relevance 0
The EGFR-gene is located on chromosome 7 and encodes for a 170 kD transmembrane glycoprotein with intrinsic tyrosine-kinase activity [15,16].
Localization (located) of EGFR-gene
17) Confidence 0.73 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1524973 Disease Relevance 0.43 Pain Relevance 0
However, in the presence of cetuximab, EGFR nuclear import and subsequent activation of DNA repair mechanisms after radiation exposure were inhibited, and radiosensitivity was enhanced (Dittmann et al 2005).
Localization (import) of EGFR
18) Confidence 0.70 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.85 Pain Relevance 0
EGFR can also translocate to the nucleus where it activates or represses the production of various effector proteins.
Localization (translocate) of EGFR in nucleus
19) Confidence 0.70 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2921255 Disease Relevance 0.22 Pain Relevance 0
After extensive washing the membranes were incubated with cocktail of biotin-conjugated anti-EGFR was used to detect phosphorylated EGFR on activated receptors.
Localization (detect) of EGFR
20) Confidence 0.68 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2777152 Disease Relevance 0.32 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox